Lilly Jaypirca data shows extended progression-free survival in CLL
Source: SeekingAlpha
2026-04-13 08:13:05 ET
More on Eli Lilly
- Even After Shedding Some Weight, Eli Lilly and Company Isn't Prime For An Upgrade
- Foundayo Explained: Lilly's New Weight Loss Pill And The Amazon Effect
- Eli Lilly Vs. Amgen: Who Leads Obesity And IMIDs
- Amazon to sell Eli Lilly’s weight loss pill via same day delivery
- Eli Lilly launches new weight loss pill Foundayo in U.S.
Read the full article on Seeking Alpha
For further details see:
Lilly Jaypirca data shows extended progression-free survival in CLL
Eli Lilly and Company
NASDAQ: LLY
LLY Trading
-1.79% G/L:
$912.09 Last:
721,677 Volume:
$923.50 Open:
LLY Latest News
April 16, 2026 10:00:00 am
Lilly confirms date and conference call for first-quarter 2026 financial results announcement
